Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL12 | P48061 | 9/20 | 0.82 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.82 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.82 |
| ▸ | TUBB | P07437 | 1/20 | 0.82 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.82 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.82 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.82 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.82 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.82 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.82 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.82 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.82 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.82 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.82 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.82 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.82 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.82 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.80 |
| ▸ | PDE4A | P27815 | 1/20 | 0.77 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598905 | 1.00 | CXCL12 (0.82) | CXCL12ABCG2TUBB4ATUBBTUBA3C | |
| SCHEMBL12677857 | 0.95 | CXCL12 (0.89) | CXCL12ABCG2TUBB4ATUBBTUBA3C | |
| SCHEMBL30384490 | 0.95 | CXCL12 (0.89) | CXCL12ABCG2TUBB4ATUBBTUBA3C | |
| SCHEMBL25193952 | 0.95 | CXCL12 (0.89) | CXCL12ABCG2TUBB4ATUBBTUBA3C | |
| SCHEMBL17227545 | 0.92 | CXCL12 (0.77) | CXCL12ABCG2TUBB4ATUBBTUBA3C | |
| SCHEMBL30383354 | 0.91 | CAPN1 (0.82) | CXCL12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30383698 | 0.91 | CAPN1 (0.82) | CXCL12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15288998 | 0.91 | TUBB4A (0.82) | CXCL12ABCG2TUBB4ATUBBTUBA3C | |
| SCHEMBL597849 | 0.91 | CAPN1 (0.82) | CXCL12TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL597850 | 0.91 | CAPN1 (0.82) | CXCL12TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2019-08-01 | — | — | US | disclosed |
| EP-3188721-B1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LTD (IE) | 2019-06-12 | — | — | EP | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140079653-A1 | ULTRAVIOLET ABSORBER | KAO CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| WO-2013136770-A1 | ULTRAVIOLET ABSORBER | KAO CORPORATION (JP) | 2013-09-19 | — | — | WO | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | CXCL12 3843/4885ABCG2 842/4885TUBB4A 67/4885 |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | CXCL12 3714/4885ABCG2 629/4885TUBB4A 63/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | CXCL12 2113/4885ABCG2 2380/4885TUBB4A 226/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | CXCL12 3843/4885ABCG2 842/4885TUBB4A 67/4885 |
| US-20140079653-A1 | ULTRAVIOLET ABSORBER | ERCC1, UNG, ERCC4 | CXCL12 3285/4885ABCG2 87/4885TUBB4A 1567/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | CXCL12 2113/4885ABCG2 2380/4885TUBB4A 226/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CXCL12 3843/4885ABCG2 842/4885TUBB4A 67/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | CXCL12 3714/4885ABCG2 629/4885TUBB4A 63/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CXCL12 3843/4885ABCG2 842/4885TUBB4A 67/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CXCL12 3843/4885ABCG2 842/4885TUBB4A 67/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | CXCL12 3714/4885ABCG2 629/4885TUBB4A 63/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | CXCL12 2895/4885ABCG2 4415/4885TUBB4A 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.